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Abstract The types, interpretation, and use of first- and
second-trimester aneuploidy screening are often unclear for
many women. This impairs appropriate decision making and
understanding of the implications of prenatal genetic testing
options. The purpose of this study was to examine the utiliza-
tion of Stepwise Sequential screening in our Midwestern
population, demographic factors associated with choice of
screening and method of risk reporting and it’s potential
impact on women’s choices. First trimester screening was
performed for 2,634 women during the study period. Results
were not reported or “framed” as “positive” or “negative”.
Rather, the specific age-risk and screen-risk for T21 were
relayed, along with options for follow-up Stepwise
Sequential screening and invasive testing. Nearly 80 % of
women declined Stepwise Sequential screening. Minorities
and women of lower education were least likely to pursue
further screening. Less than 4 % of the study population
elected invasive testing. First trimester screening was associ-
ated with a 53 % reduction in amniocenteses and 20 % fewer
CVS’s compared to pre-first trimester screening availability.
Reporting age-and screen-risks for T21, rather than classify-
ing results as “positive” or “negative” based on a pre-
determined threshold, was associated with a low uptake of
further testing.
Keywords Aneuploidy . Screening . First trimester . Second
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Introduction
In January 2007, the American College of Obstetricians and
Gynecologists (ACOG) Practice Bulletin Number 77 recom-
mended “screening and invasive diagnostic testing should be
available to all women who present for prenatal care before
20 weeks of gestation regardless of maternal age”. Several
strategies for screening have been proposed based on the first
trimester combined test (nuchal translucency (NT) measure-
ment and biochemical markers) and second trimester maternal
serum quadruple (Quad) screen. The highest detection rates
and lowest screen positive rates have been reported for
Integrated screening. This includes first trimester nuchal trans-
lucency, pregnancy-associated plasma protein A (PAPP-A)
and human chorionic gonadotropin (hCG) plus maternal se-
rum Quad screening in the mid-trimester, with the results
provided only after all tests are completed. Patient anxiety
during the delay between presentation for screening and re-
sults make this an unacceptable option for many patients.
Proposed alternative screening options include Stepwise
Sequential screening and Contingent Sequential screening
based on classifying women as high- or low-risk using a
predetermined threshold (American College of Obstetricians
and Gynecologists ACOG 2007). Stepwise Sequential screen-
ing is first trimester combined testing plus maternal serum
Quad screening with results provided after each test.
Contingent Sequential screening is first trimester combined
testing with only women having a risk between 1:30 and
1:1,500 for trisomy 21 (T21) proceeding to maternal serum
Quad screening.
Themanner in which risks are communicated can influence
how this information is utilized. Prenatal aneuploidy
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screening results are often reported or “framed” as “positive”
or “negative” based on a defined threshold. This is usually the
risk of a 35-year old woman having a child with T21 or
trisomy 18 (T18). However, there is little information about
the effects of using verbal descriptions of risk versus numer-
ical data. In a survey of 169 British antenatal clinics about the
method of communicating Down syndrome screen negative
results, 44 % used a verbal phrase (low risk, screen negative,
within normal limits, not needing further action, among
others), 16 % gave a numeric risk figure and 40 % used both
a verbal phrase and numeric risk (Marteau 1999). The value of
these different techniques for discussing risks is uncertain.
The goals of this study were to examine: 1- the uptake of
Stepwise Sequential screening in our primarily urban,
Midwestern population, 2- the potential affects of ethnicity,
education and proximity to the medical center on willingness
to proceed with further testing, and 3- our method of risk
reporting, which emphasized a woman’s age-risk for T21
and adjusted risk after screening, rather than classifying a
result as “positive” or “negative”, or high-risk, or low-risk.
Methods
This is a retrospective cohort study of all patients who com-
pleted first trimester NT and biochemical screening at our
institution between June 2007 and February 2010. This study
was approved by theWashington University Human Research
Protection Office, which waived informed consent. Inclusion
criteria included women with singleton gestations who com-
pleted combined first trimester screening with NT and the
serum markers PAPP-A and hCG. For the first 3 months of
the study period, the laboratory utilized at this institution used
total beta-hCG. Thereafter, free beta-hCG was the analyte
employed. Exclusion criteria included multiple gestations,
blood testing not performed or analyzed and inability to obtain
a NTmeasurement. All NT measurements were performed by
physicians or sonographers certified in NT measurement by
either the Fetal Medicine Foundation or the Nuchal
Translucency Quality Review (NTQR) program.
Patient’s were categorized at the time of their first trimester
screening visit into one of three groups as follows: U =
undecided as to whether they wished to proceed with
Stepwise Sequential screening; Y = yes, they planned to
pursue Stepwise Sequential screening; or N = no, they do
not plan to have Stepwise Sequential screening. Results of
first trimester screening were not reported as positive or neg-
ative. The phone call and/or letter informing patients of their
first trimester screen results indicated the patient’s age-risk for
(T21) and trisomy 18 (T18) and their revised risks for same
based on the NT and biochemical markers. The determination
of whether a patient was of high enough risk to warrant further
screening or testing was at the patient’s discretion. All phone
calls and/or result letters also again reviewed the patient’s
subsequent options, including no further screening, maternal
serum Quad screening, mid-trimester ultrasound and invasive
testing via chorionic villus sampling (CVS) or amniocentesis.
The patient’s decision about whether to proceed with Stepwise
Sequential screening (both before and after their first trimester
screening results) were recorded in a computerized database
for subsequent correlation with variables including ethnicity,
level of education, distance from our medical center, NT
measurement, crown rump length, age- and screen-risks for
T21, results of invasive testing and pregnancy outcomes.
In order to assess the impact of non-invasive first trimester
screening and Stepwise Sequential screening (first trimester
screening plus maternal serum Quad screening) on the utili-
zation of amniocentesis and CVS, the number of these proce-
dures was compared as follows: for a 2-year period prior to the
initiation of first trimester screening (January 2000–December
2001), for a 2-year period when first trimester screening was
utilized but prior to the availability of Stepwise Sequential
screening (June 2005–May 2007) and for the 2-year period
following initiation of Stepwise Sequential screening (July
2007–June 2009).
Relationship between decision status (Yes, No, Undecided)
and various characteristics were compared using the chi-
square test or Fisher’s exact test, as appropriate. Differences
in the counts of invasive procedures performed across time
periods were evaluated using simple Poisson regression
models, where time period (2000–2001, 2005–2007, and
2007–2009) was included using indicator variables.
Results
First trimester only screening was available at our institution
beginning in 2003. The option of Stepwise Sequential screen-
ing began to be routinely offered in June 2007. The study
population consists of 2,643 patients who met inclusion
criteria during the study period (June 2007–February 2010).
During this time, an acceptable NT measurement was unable
to be obtained in 8 patients (0.3 % of the initial study popu-
lation). At the time of the first trimester examination, 1,926
(72.8 %) were undecided regarding Stepwise Sequential
screening (U group) pending their first trimester results. 434
patients (16.4%) indicated they planned to return for Stepwise
Sequential screening, regardless of their results (Y group) and
283 patients (10.7 %) declined Stepwise Sequential screening
at the time of their first trimester screening (N group).
The numbers of patients who actually pursued Stepwise
Sequential screening are listed in Table 1. This included a
minority of the Undecided and No groups (14.9 % and 1.4 %,
respectively) and only 56.4 % of those who originally
intended to have Stepwise Sequential screening. Overall,
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79.8% of the study population elected not to pursue follow-up
screening.
The relation between education level and choice of screen-
ing is presented in Table 2. In the group of women who did not
plan to pursue Stepwise Sequential screening there were a
significantly greater number who were not high school grad-
uates and significantly fewer who were college graduates
compared to women in the other two groups. Table 3 demon-
strates that women who declined Stepwise Sequential screen-
ing were more likely to be Black and Hispanic and less likely
to beWhite, than women in the other groups. Table 4 indicates
that distance from the medical center did not correlate with the
decision to pursue or decline Stepwise Sequential screening.
Tables 5 and 6 demonstrate that the percentages of women
at risk for T21 were similar between the groups.
The number of patients whose first trimester screen-risk for
T21 exceeded their age-risk, and their choice of follow-up, is
depicted in Table 7. Overall, 126 patients (4.8 % of the study
population) had a first trimester screen-risk for T21 which was
greater than their age-risk. Each group had a similar percent-
age of these patients. Of these, 73(57.9 %) women elected not
to have follow-up Stepwise Sequential screening or diagnostic
testing, 24(19.8 %) had Stepwise Sequential screening only
and 29(23.0 %) had invasive testing via CVS (N=11) or
amniocentesis (N=18). The karyotype was normal in 27/29.
There was one case of 47, XY, +21 and one apparently
balanced Robertsonian translocation between chromosomes
13 and 14. Women who originally declined Stepwise
Sequential screening were significantly less likely to pursue
invasive testing than women in the other two groups.
A total of 91(3.4 % of the study population) women had
invasive testing by amniocentesis (N=76) or CVS (N=15)
during the study period. In 59(64.8 %), the age-risk for T21
was greater than the screen-risk. The karyotype was normal in
87/91(95.6 %). There were three cases of T21 and the afore-
mentioned translocation. In two of the three T21 cases, the
maternal age risk was greater than the screen risk (The age
risks were 1:43 and 1:235 versus screen risks of 1:96 and
1:246, respectively).
The number of invasive procedures performed prior
to the availability of first trimester screening, following
initiation of first trimester screening and following the
availability of Stepwise Sequential screening is indicated
in Table 8. The indications for invasive testing were
varied and included AMA, abnormal ultrasound find-
ings, abnormal screening, and family history of aneu-
ploidy. All patients in the study population had screen-
ing prior to their invasive testing. The number of am-
niocenteses in our center declined by 51.4 % following
the availability of first trimester screening with a further
17.4 % reduction upon initiation of Stepwise Sequential
screening. The reduction was significant between all
time periods. The number of CVS procedures declined
by 19.2 % following availability of first trimester
screening. There was a significant reduction in the
number of CVS procedures from pre-first trimester
screening and its utilization. However, there was no
significant difference in the number of CVS procedures
between availability of first trimester screening and
Stepwise Sequential screening.
Table 1 Stepwise sequential
screening following first trimester
combined screen
Group N No SS screening Follow-up SS screening P
Undecided 1,926 (72.9 %) 1,639 (85.1 %) 287 (14.9 %) <0.0001
Yes 434 (16.4 %) 190 (43.8 %) 244 (56.2 %)
No 283 (10.7 %) 279 (98.6 %) 4 (1.4 %)
2,643 (100 %) 2,108 (79.8 %) 535 (20.2 %)
U vs Y <0.0001
U vs N <0.0001
Yvs N <0.0001
Table 2 Eduction level and de-
cision to pursue stepwise sequen-
tial screening
Group N Some high school HS grad some college College grad post grad P <0.0001
Undecided 1,923 68 (3.5 %) 501 (26.1 %) 1,354 (70.4 %)
Yes 434 11 (2.5 %) 115 (26.5 %) 308 (71.0 %)
No 282 22 (7.8 %) 111 (39.4 %) 149 (52.8 %)
∑ 2,639 101 (3.8 %) 727 (27.5 %) 1,811 (68.6 %)
U vs. Y 0.58
U vs. N <0.0001
Yvs N <0.0001
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Discussion
In our population, only 20 % of women having first trimester
screening, elected to pursue Stepwise Sequential screening
with 3.4 % undergoing invasive testing. Proximity to the
medical center did not affect the likelihood of our population
to return for Stepwise Sequential screening.
Women of lower education level and Black or Hispanic
ancestry were least likely to desire further screening or testing
following their first trimester screen results. The reason for
this disparity is uncertain. It is possible this represents lower
health literacy in these groups with less of an appreciation or
even misinterpretation of the consequences and benefits of
Stepwise Sequential screening. The amount of information to
be collected and conveyed at the initial prenatal visit, in
addition to decisions regarding aneuploidy screening, can be
overwhelming even for relatively medically sophisticated
women. Perhaps women of lower education and minorities
should be offered pre-conception counseling so that they have
more time to consider the benefits and risks of genetic screen-
ing and testing. It may also be that women in these groups are
more conservative in their approach to prenatal screening
overall, and consider themselves less likely to act on the basis
of a “positive” result. Additionally, it is possible that their
perception and tolerance of risk may be different than women
in other groups due to differences in their own frame of
reference.
How results are reported, and its potential impact on how a
woman interprets this information was a focus of this work. A
woman whose screen-risk of T21 is 1:310 will be considered
to have a “negative” result and may well be reassured even if
this is higher than her age-related risk. By the same token, a
woman with a screen-risk of 1:260 will have a result reported
as “positive” or elevated risk even if it is a significant reduc-
tion compared to her age-related risk. The difference between
0.32 % (1:310) and 0.38 % (1:260) is not great but the
implications for a woman’s attitude, anxiety and subsequent
plans for screening and testing may be significant. For many
patients, interpretation of risk is influenced more by emotions
than by facts (Paling 2003). The manner in which risk infor-
mation is presented or “framed” assumes special importance
when it involves communication of genetic testing results.
Framing can significantly impact health choices (Edwards
et al. 2001; O’Doherty and Suthers 2007). Negative framing,
in this case the designation of a test result as indicating
elevated risk, may have a greater impact on the perceived
need for follow-up testing, than the numerical description of
risk, which is more understandable to many patients. This is
consistent with evidence that numeric communication of risk
is often preferred by individuals when making major medical
decisions (Lipkus 2007). The intent of our approach was that
the women’s perceptions of their risks would be based on their
screen-risk for T21 relative to their age-risk, and not neces-
sarily relative to the risk of a 35-year old woman.
Table 3 Ethnicity and decision to pursue stepwise sequential screening
Ethnicity
Group N White Black Asian Hisp Other P <0.0001
Undecided 1,926 1,395 (72.4 %) 293 (15.2 %) 106 (5.5 %) 49 (2.5 %) 83 (4.3 %)
Yes 434 326 (75.1 %) 50 (11.5 %) 18 (4.1 %) 8 (1.8 %) 32 (7.4 %)
No 283 165 (58.3 %) 71 (25.1 %) 10 (3.5 %) 17 (6.0 %) 20 (7.1 %)
∑ 2,643 1,886 (71.4 %) 414 (15.7 %) 134 (5.1 %) 74 (2.8 %) 135 (5.1 %)
U vs. N 0.01
U vs. N <0.0001
Yvs. N <0.001
Table 4 Distance from medical
center and decision to pursue
stepwise sequential screening
Miles P
Group N 0–20 21–50 >50 0.14
Undecided 1,926 1,293 (67.1 %) 507 (26.3 %) 126 (6.5 %)
Yes 434 284 (65.4 %) 114 (26.4 %) 36 (8.3 %)
No 283 170 (60.1 %) 88 (31.1 %) 25 (8.8 %)
∑ 2,643 1,747 (66.1 %) 709 (26.8 %) 187 (7.1 %)
U vs. Y 0.42
U vs. N 0.05
Y vs. N 0.32
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With respect to implications for genetic counselors, an
appreciation of the potential impact of framing as it relates
to prenatal screening results is appropriate. The way informa-
tion is presented can significantly affect decisions made. It is
important that the magnitude of the increase in risk, whether
increased or decreased, be presented as simply and effectively
as possible. Classifying a result as “positive” because the T21
risk exceeds that of a 35-year old, may be less useful and more
frightening than expressing the screen-risk relative to a
woman’s age-risk. Verbal communication of risk is commonly
used in other areas of life (it is “likely” to rain, a certain
condition is “common”, etc.). The limitations of this approach
when applied to medical screening is that it lacks precision
due to variability in interpretation of what represents increased
risk. Describing a result as “negative” has the effect of pro-
viding maximum reassurance, even is cases where the screen
related-risk is similar to a woman’s age-related risk.
Conversely, informing a woman her result is “positive” is
often associated with great stress, which may be ameliorated
when the numeric risk is placed in the context of a woman’s
age-related risk. Because of the imprecision associated with
terms like positive, negative, high-risk, and low-risk, it is our
recommendation that when screen results are discussed, nu-
meric risks should be stressed over verbal description of risks.
It is possible results presented in this manner facilitate in-
formed choice. Additionally, an absolute number as expressed
by the screen-risk provides the patient with an estimate not
only of the risk for T21, but also the chance the pregnancy is
not at risk. A screen-risk of 1:1,000 or less, not an unusual
result, predicts not only a 1:1,000 chance for T21, but roughly
a 999:1,000 a fetus does not have T21. The numerical expres-
sion of risk allows not only a precise estimate of the risk of a
problem, but also the likelihood of normalcy or absence of a
condition. In this way, risks can be presented in a balanced
manner, not merely focusing on whether a result is positive or
negative.
Unlike other forms of medical screening, which are de-
signed to predict or prevent disease, prenatal screening pro-
vides women with information allowing them to make in-
formed choices regarding their prenatal care as well as con-
tinuation or interruption of their pregnancy. In our approach, a
“positive” test can be defined practically as one which
prompts further screening and/or diagnostic testing.
Similarly, a “negative” test provides sufficient reassurance to
obviate further testing or to allow diagnostic testing via am-
niocentesis rather than CVS. As demonstrated by the First and
Second Trimester Evaluation of Risk (FASTER) Trial, detec-
tion rates and screen positive rates are modestly improved
with the addition of maternal serum Quad screening (Ball,
et al. 2007). However, the majority of our population did not
require or desire this information to make informed choices
regarding their pregnancy.While this may reflect the generally
conservative nature of our population, it may also indicate the
information, when presented as described, facilitates women’s
understanding of the change in absolute risk for fetal trisomy
relative to their baseline, age-related risk. This is consistent
with evidence that responses to risk often depend on that to
which the calculated risk is being compared (Johnson 2004). It
also reflects the contextualized nature of prenatal risk assess-
ment and the observation that objective risk and perceived risk
are often dissimilar (Marteau 1999). The influence of other
factors, including religious, economic, and the perceived ef-
fects of a child with aneuploidy on the existing family struc-
ture also play an important role in the patient interpretation of
and response to screening results (Garcia et al. 2012).
The availability of first trimester screening and Stepwise
Sequential screening were each associated with a significant
Table 5 Age risk for T21 and decision to pursue stepwise sequential
screening
Group ≥1:50 1:51–1:270 >1:270 P*
Undecided (N-1,926) 44 (2.3 %) 896 (46.5 %) 986 (51.2 %) 0.26
Yes (N-434) 17 (3.9 %) 204 (47.0 %) 213 (49.1 %)
No (N-283) 9 (2.6 %) 140 (49.5 %) 134 (47.3 %)
U vs. Y 0.14
U vs. N 0.37
Y vs. N 0.75
*Fishers exact test
Table 6 Screen risk for T21 and
decision to pursue stepwise se-
quential screening
*Fishers exact test
Group ≥1:50 1:51–1:270 >1:270 P* 0.63
Undecided (N-1,926) 26 (1.3 %) 86 (4.5 %) 1,814 (94.2 %)
Yes
(N-434) 7 (1.6 %) 21 (4.8 %) 406 (93.5 %)
No
(N-283) 7 (2.5 %) 13 (4.6 %) 263 (92.9 %)
Uvs. Y 0.79
U vs. N 0.30
YvsN. 0.74
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decline in the number of amniocenteses performed at our
institution. The smaller decrease between first trimester and
Stepwise Sequential screening can be at least partially attrib-
uted to the fact only 20 % of our population elected sequential
screening. First trimester screening was also associated with a
significant reduction in the number of CVS procedures
performed.
The option of Stepwise Sequential screening did not further
reduce the number of CVS’s. This is not unexpected as most
pregnancies at increased risk for fetal aneuploidy are identi-
fied earlier with the option for first trimester diagnostic testing,
obviating the need for mid-trimester testing. This also reflects
some cases where the screen risk was lower than the maternal
age risk but the reduction was not adequately reassuring,
resulting in the decision to proceed with earlier diagnostic
testing. With respect to the utilization of invasive procedures,
our findings are similar to those described by others. Wray,
et al. reported that availability of first trimester screening
coincided with more women of advanced maternal age
(AMA) referred for early genetic counseling. In 2001, 68
women were seen for early genetic counseling versus 172 in
2003. The rates of invasive testing dropped significantly from
pre- to post-first trimester screening availability (71 % vs
26 %, p<0.01). The types of invasive testing were not spec-
ified (Wray et al. 2005). Benn, et al. reviewed a series of
nearly 2000 amniocentesis and CVS samples from 1991 to
2002. They reported a 50 % reduction in the number of
invasive procedures over this time. This was attributed to
advances in maternal serum screening and mid-trimester so-
nography. However, this was before the widespread applica-
tion of first trimester screening and it was not stipulated
whether nuchal translucency or first trimester serum markers
were included in this analysis. Additionally, CVS specimens
comprised only 4.3 % of their samples (Benn, et al. 2004).
It is felt that first trimester screening is the major reason for
the decrease in invasive procedures. In our experience, prena-
tal care providers have embraced this technology and routine-
ly offer this option even to at-risk women, ahead of invasive
testing. It is possible this predisposes women to have confi-
dence in first trimester screening sufficient to obviate the need
for absolute reassurance via invasive testing with its attendant
risks. It is also possible the risks of invasive testing are
exaggerated in many womens’ minds. There may also be an
element of “quit while ahead”. If you have a result you like,
why seek additional information which may detract from your
peace of mind? In our opinion, receiving a very low risk early
in pregnancy gives many women the reassurance that their
pregnancies are “normal”. It may be that this makes it easier
for some to believe that further testing is unnecessary. Similar
reassurance can be provided by maternal serum Quad screen-
ing, but not until later in the pregnancy.
The main limitation of our study is that it reflects a local
population whose attitudes regarding screening and testing
and thresholds for pursuing follow-up may not be reflective
of women in other parts of the country. Additionally, while
most cases of T21 and T18 are reliably diagnosed postnatally,
the majority of women did not have cytogenetic testing and
postnatal follow-up was unavailable for 64 patients.
Therefore, other undetected cases of aneuploidy cannot be
excluded. Other limitations include the fact that there is no
control population of women who did not receive results
reported as “positive” or “negative”. We are unable to directly
compare our approach with other methods of risk communi-
cation. It is also plausible that both health care providers and
Table 7 Screen Risk for T21
Greater than Age Risk and Choice
of Follow-up
*Fisher's exact test







Undecided (n-1,926) 91 (4.7 %) 0.98 52 (57.9 %) 15 (19.0 %) 24 (26.4 %)
Yes (N-434) 21 (4.8 %) 8 (38.1 %) 9 (42.9 %) 4 (19.0 %)
No (N-283) 14 (4.6 %) 13 (92.9 %) 0 1 (7.1 %)
∑ 2,643 126 (4.8 %) 73 (57.9 %) 24 (19.0 %) 29 (23.0 %)
U vs. Y 0.92 U vs. Y 0.05
U vs. N 0.87 U vs N 0.04
Y vs. N 0.99 Y vs. N 0.002
Table 8 Number of Invasive Procedures Before and After First Trimester and Stepwise Sequential Screening Availability
Procedure Pre-FTS FTSa only SSb Avail p, pre-FTS vs FTS only p, FTS only vs. SS avail
Amniocentesis 1,632 793 655 p<0.0001 p<0.0001
CVS 494 399 371 P<0.001 P=0.31
a First trimester screening
b Sequential screening
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patients are used to considering medical test results as normal
or abnormal, and may be less familiar with the notion of
comparative quantitative risk assessment. Lastly, while non-
invasive prenatal testing with cell free fetal DNA is presently
limited, the anticipated expanded application of such technol-
ogy will likely limit the utilization of current screening para-
digms. Therefore, other risk communication and counseling
strategies will ultimately need to be developed to suit different
circumstances.
Conclusion
In summary, communication of risk for aneuploidy is especially
important and challenging in the prenatal setting. Following the
performance of first trimester screening, 80 % of our study
population ultimately declined follow-up testing, including
nearly one-half of those who initially planned to pursue
Stepwise Sequential screening. The policy of providing patients
with their results by specifying their age-related risk, their
revised screen-related risk and further options, without classi-
fying results as “positive” or “negative”, seemed to communi-
cate risk in a manner which was understandable and clinically
useful, with minimal bias. This also resulted in far fewer
Stepwise Sequential screens being performed than would be
predicted using most current sequential screening paradigms.
The introduction and increasing utilization of first trimester
combined screening has been accompanied by a steady de-
crease in the number of invasive diagnostic procedures, which
is more pronounced for amniocentesis than CVS.
Acknowledgments We thank Ryan Colvin, Division of Clinical Re-
search, Department of Obstetrics and Gynecology, Washington Univer-
sity School of Medicine, for his assistance with statistical analysis.
All procedures followed were in accordance with the clinical standards
of the responsible committee on human experimentation and the Helsinki
Declaration of 1975 as revised in 2000. This study was approved by the
Washington University Human Research Protection Office, which
waived informed consent.
Conflict of Interest Jeffrey Dicke, Lindsey Van Duyne and Rachael
Bradshaw declare that they have no conflict of interest.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
American College of Obstetricians and Gynecologists (ACOG). (2007).
ACOG Practice Bulletin 77: Screening for fetal chromosome abnor-
malities. Obstetrics and Gynecology, 109, 217–227.
Ball, R. H., Caughey, A. B., Malone, F. D., Nyberg, D. A.,
Comstock, C. H., Saade, G. R., et al. (2007). First- and
second-trimester evaluation of risk for down syndrome. Obstetrics
and Gynecology, 110, 10–17.
Benn, P. A., Egan, J. F. X., Fang, M., & Smith-Bindman, R. (2004).
Changes in the utilization of prenatal diagnosis. Obstetrics and
Gynecology, 103, 1255–1260.
Edwards, A., Elwyn, G., Covey, J., et al. (2001). Presenting risk infor-
mation—a review of the effects of “framing” and other manipula-
tions on patient outcomes. Journal of Health Communication, 6,
61–82.
Garcia, E., Timmermans, D. R. M., & van Leeuwen, E. (2012). Parental
duties and prenatal screening: does an offer of prenatal screening
lead women to believe that they are morally compelled to test?
Midwifery, 28, e837–e843.
Johnson, B. B. (2004). Risk comparisons, conflict, and risk acceptability
claims. Risk Analysis, 24, 131–145.
Lipkus, I. M. (2007). Numeric, verbal, and visual formats of conveying
health risks: suggested best practices and future recommendations.
Medical Decision Making, 27, 696–713.
Marteau, T. M. (1999). Communicating genetic risk information. British
Medical Bulletin, 55(2), 414–428.
O’Doherty, K., & Suthers, G. K. (2007). Risky communication: pitfalls in
counseling about risk, and how to avoid them. Journal of General
Counsel, 16, 409–417.
Paling, W. (2003). Strategies to help patients understand risks. BMJ, 327,
745–748.
Wray, A. M., Ghinini, A., Alvis, C., Hodor, J., Landy, H. G., &
Poggis, H. (2005). The impact of first trimester screening on
AMA patients’ uptake of invasive testing. Prenatal Diagnosis, 25,
350–353.
880 Dicke, Van Duyne and Bradshaw
